HythamAl-MasriMD
Pathology • Tinley Park, ILHematopathology, Anatomic Pathology, Clinical Pathology
Physician
Are you Dr. Al-Masri?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 36 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8150 185th St Ste A60487
Tinley Park, IL 60487Phone+1 708-444-0444- Is this information wrong?
Summary
- Dr. Hytham Al-Masri, MD is a pathologist in Tinley Park, Illinois. He is currently licensed to practice medicine in Illinois and Michigan.
Education & Training
Loyola University Medical CenterFellowship, Hematopathology, 2003 - 2004
HealthPartners InstituteResidency, Pathology-Anatomic and Clinical, 1996 - 2001
Damascus University Faculty of MedicineClass of 1991
Certifications & Licensure
IL State Medical License 2001 - 2026
MI State Medical License 2003 - 2010
Publications & Presentations
PubMed
- 2 citationsA Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma.Mingjun Zhang, Falon Gray, Ian Cushman, Andrew Wurmser, Henry Chan, Suzana Couto, Maria Wang, Yumi Nakayama, Patrick Hagner, Hytham Al-Masri, Shuntae Williams, Sarah H...> ;Modern Pathology. 2023 Apr 1
- 37 citationsConcordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon Rebelatto, Jill Walker> ;Diagnostic Pathology. 2019 Sep 2
- 246 citationsAgreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.Marianne Ratcliffe, Alan Sharpe, Anita Midha, Craig Barker, Marietta Scott, Paul Scorer, Hytham Al-Masri, Marlon Rebelatto, Jill Walker> ;Clinical Cancer Research. 2017 Jul 15
- Join now to see all
Press Mentions
Hematogenix Launches FDA Approved Companion Diagnostic Immuno-Oncology Test for Triple-Negative Breast CancerMarch 13th, 2019
